Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073918 · ClinicalTrials.gov registry record · Phase 2
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 2 study of Anaplastic Large Cell Lymphoma and Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
- 1
- Study location
NCT00073918 is a Phase 2 study of Anaplastic Large Cell Lymphoma and Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 111 participants, above the 56-participant average among 25 other Anaplastic Large Cell Lymphoma trials with a reported enrollment target (98% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00073918, a Phase 2 study of Anaplastic Large Cell Lymphoma and Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well giving iodine I 131 tositumomab together with etoposide and cyclophosphamide followed by autologous stem cell transplant works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Combining a radiolabeled monoclonal antibody with combination chemotherapy before autologous stem cell transplant may kill more cancer cells
Conditions Studied
Interventions
- DRUG cyclophosphamide
- PROCEDURE quality-of-life assessment
- DRUG etoposide
- PROCEDURE peripheral blood stem cell transplantation
- RADIATION iodine I 131 tositumomab
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 1999-02 |
| Est. Completion | 2011-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073918
The ClinicalTrials.gov registry entry for NCT00073918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 56-participant average among 25 other Anaplastic Large Cell Lymphoma trials with a reported enrollment target (98% higher). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Anaplastic Large Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00073918 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00073918 about?
NCT00073918 is a clinical study titled "Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". This phase II trial is studying how well giving iodine I 131 tositumomab together with etoposide and cyclophosphamide followed by autologous stem cell transplant works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Radiolabeled monoclonal antibodies, such as iodine I 131 to...
What is the current status of trial NCT00073918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 1999-02. Estimated completion is 2011-10-02.
What conditions does trial NCT00073918 study?
This clinical trial studies the following conditions: Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma.
What interventions are being tested in trial NCT00073918?
The interventions under investigation include: cyclophosphamide (DRUG), quality-of-life assessment (PROCEDURE), etoposide (DRUG), peripheral blood stem cell transplantation (PROCEDURE), iodine I 131 tositumomab (RADIATION).
Who is sponsoring clinical trial NCT00073918?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00073918 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anaplastic Large Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
COMPLETED · Phase 2
-
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
COMPLETED · Phase 2
-
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
COMPLETED · Phase 2
-
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
COMPLETED · Phase 2
Explore more on PlainTrial
Anaplastic Large Cell Lymphoma
All registered trials for this condition
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.